Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MARAVIROC

All products: general benefit

Other products in the same Health Canada class (J05A, J05AX) — coverage varies; not interchangeable

  • Letermovir (Prevymis): not a benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, Not a benefit
  • Atazanavir (Reyataz): general benefit, Not a benefit

48 more in the class list below

Celsentri · DIN 02299852 · 300mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

1-855-525-5300 · Canadian ViiV support and registration

Manufacturer assistance is not subtracted from public estimates. Final out-of-pocket cost is not established.

Assistance conditions and dated sources

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

1 brand, same coverage
Celsentri · DIN 02299852 Manufacturer: ViiV Healthcare ULC; listing date 2014-04-30 Health Canada: Marketed since 2014-08-30 · brand CELSENTRI · ATC J05AX09 MARAVIROC · form Tablet · route Oral · ingredients MARAVIROC 300 MG · company Viiv healthcare ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $16.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78520 · Verify on the e-Formulary ↗ (DIN 02299852)

Source record
DIN 02299852: Celsentri Raw flags: sec3=Y Item: 081800112; group id 99; item number 0175; lccId None; manufacturer id VIH Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $22.0100; ministry $16.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299852 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78520
Interchangeable products
Waymade-Maraviroc · DIN 02561948 · $16.2156
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

LETERMOVIR

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 240mg, 480mg · Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CELSENTRI (maraviroc), in combination with other antiretroviral agents, is indicated for adult patients infected with CCR5-tropic HIV-1. The following points should be considered when initiating therapy with CELSENTRI: • CCR5 tropism should be confirmed using a highly sensitive tropism assay prior to initiation of CELSENTRI therapy. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on CELSENTRI (see 15 MICROBIOLOGY). • CELSENTRI is not recommended in patients infected with dual/mixed- or CXCR4-tropic HIV-1; efficacy in this patient population was not demonstrated in a Phase 2 Study. 1.1 Pediatrics Pediatrics (<18 years of age): The safety and efficacy of CELSENTRI have not been established in pediatric patients. 1.2 Geriatrics Geriatrics (>65 years of age): In general, caution should be exercised when administering CELSENTRI in elderly patients (see 7 WARNINGS AND PRECAUTIONS, 7.1 Special Population, 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00071613.PDF PM date: SEP 19, 2007 Source product: CELSENTRI; DIN 02299844; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.